TY - JOUR
T1 - Combined therapy with amphotericin B and caspofungin in an experimental model of disseminated histoplasmosis
AU - Rodríguez-Arellanes, Gabriela
AU - Taylor, Maria Lucía
AU - Pérez-Torres, Armando
AU - Curiel-Quesada, Everardo
AU - Vargas-Mendoza, Carlos Fabian
AU - Martinez-Rivera, Maria Angeles
PY - 2009/1
Y1 - 2009/1
N2 - Objective. To assess the effect of amphotericin B and caspofungin, as well as their combinations in the therapy of experimental disseminated histoplasmosis. Material and methods. BALB/c mice were intraperitoneally infected with four different strains of Histoplasma capsulatum and given to antifungal treatments. The response to intraperitoneal therapy with amphotericin B (0.5, 1.0, and 2.0 mg/kg of body weight) or caspofungin (10 mg/kg of body weight) and their combinations, was evaluated by the quantification of yeast colony-forming units (CFU) per gram of spleen or lung, from each animal. Additionally, the pathogen was monitored histopathologically in the excised organs. Data were analyzed with the Kruskall-Wallis and Tukey tests. Results. Caspofungin was more effective than amphotericin B in reducing the CFU/ g. A synergistic effect was observed when caspofungin (10 mgI kg) was combined with amphotericin B (0.5 or 1.0 mg/kg). Significant differences in CFU values, H = 119.78 (P = 0.00001), were found among the treatment groups. However, statistical analyses did not reveal significant differences, H = 2,837 (P = 0.428), in the therapeutic responses with the four H. capsulatum strains tested. Conclusion. Combined therapy with amphotericin B and caspofungin could represent an alternative treatment to be explored in severe human histoplasmosis.
AB - Objective. To assess the effect of amphotericin B and caspofungin, as well as their combinations in the therapy of experimental disseminated histoplasmosis. Material and methods. BALB/c mice were intraperitoneally infected with four different strains of Histoplasma capsulatum and given to antifungal treatments. The response to intraperitoneal therapy with amphotericin B (0.5, 1.0, and 2.0 mg/kg of body weight) or caspofungin (10 mg/kg of body weight) and their combinations, was evaluated by the quantification of yeast colony-forming units (CFU) per gram of spleen or lung, from each animal. Additionally, the pathogen was monitored histopathologically in the excised organs. Data were analyzed with the Kruskall-Wallis and Tukey tests. Results. Caspofungin was more effective than amphotericin B in reducing the CFU/ g. A synergistic effect was observed when caspofungin (10 mgI kg) was combined with amphotericin B (0.5 or 1.0 mg/kg). Significant differences in CFU values, H = 119.78 (P = 0.00001), were found among the treatment groups. However, statistical analyses did not reveal significant differences, H = 2,837 (P = 0.428), in the therapeutic responses with the four H. capsulatum strains tested. Conclusion. Combined therapy with amphotericin B and caspofungin could represent an alternative treatment to be explored in severe human histoplasmosis.
KW - Amphotericin B
KW - Antifungal drugs
KW - Caspofungin
KW - Combined therapy
KW - Histoplasmosis
UR - http://www.scopus.com/inward/record.url?scp=67649746316&partnerID=8YFLogxK
M3 - Artículo
SN - 0034-8376
VL - 61
SP - 4
EP - 10
JO - Revista de Investigacion Clinica
JF - Revista de Investigacion Clinica
IS - 1
ER -